ClinicalTrials.gg
CompletedNCT07141030Updated Nov 10, 2026

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function

A Phase 1 interventional study of GZR18 injection in Obesity/Overweight, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2025, registered Aug 2025).
Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
12th of 15
32 · median 140
Started
2025
with 5 others
Phase 1
7 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
9 of 15
Gan & Lee Pharmaceuticals.

Among the 15 studies testing bofanglutide in Obesity, this one is the 12th largest by enrollment, is one of 6 that started in 2025, is one of 7 in phase 1, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal renal function and those with mild, moderate or severe renal impairment.

The study duration for each subject in this study is up to 50 days, including a screening period of up to 14 days (Day-14 to Day-1), an 8-day dosing/observation period (Day 1 to Day 8), and a 28-day follow-up period (Day 9 to Day 36).

03

Conditions studied

  • Obesity/Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Subjects sign the Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and be able to follow the and restrictions specified in this protocol.

    2.Subjects (male or female) age ≥ 18 and ≤ 75 years at the time of signing ICF.

    3.Subjects with from signing the ICF to 8 weeks after the last dose have no family planning, are willing to adopt effective measures and have no plans for sperm donation; women of childbearing potential are not pregnant or lactating: they must have a negative pregnancy test at screening and have no unprotected sexual intercourse within 2 weeks before screening.

    4.Subjects weighing ≥ 50 kg and 20 ≤ ≤ 40 kg/m2 at screening.

    5.Subjects with normal renal function must also meet the following conditions:

    1. 90 mL/min ≤ individual's \< 130 mL/min at screening (see Appendix 2: Formulas Involved in the Protocol for the calculation formula).
    2. Subjects with normal laboratory test results, vital signs, , physical examination, chest AP view, abdominal B-ultrasound, and other examination results at screening or without abnormalities as assessed by the investigator.

    6.Subjects with renal impairment must also meet all of the following:

    1. Mild renal impairment group: 60 mL/min ≤ individual's GFR \< 90 mL/min at screening; moderate renal impairment group: 30 mL/min ≤ individual's GFR \< 60 mL/min at screening; severe renal impairment group: 15 mL/min ≤ individual's GFR \< 30 mL/min at screening.
    2. Subjects with moderate and severe renal impairment should meet the diagnostic criteria for chronic kidney disease (outpatient medical records, hospitalization medical records or laboratory test results can be used as evidence). If the subject is receiving drug therapy, a stable medication regimen (at least within 2 weeks before administration) is required.

Exclusion criteria

Exclusion Criteria:

  • 1.Subjects with allergic constitution, including those with a history of severe drug allergy or reactions, and those known or suspected to be allergic to GLP-1 drugs or their as considered by the investigator.

    2.Subjects with a history of acute or chronic pancreatitis and pancreatic injury before screening; subjects with viral hepatitis, alcoholic liver disease, hepatic cirrhosis, hepatitis and other liver diseases before screening; subjects with symptomatic gallbladder disease at screening.

    3.Subjects who routinely receive dialysis or have a history of kidney transplantation or other organ transplantation before screening.

    4.Subjects with severe infection, severe trauma, gastrointestinal surgery, or other major surgical operations within 6 months before screening.

    5.Subjects with a history of moderate or major depression, suicidal tendency or suicidal behavior before screening; or other serious mental disorders (schizophrenia, bipolar affective disorder, etc.); or other psychiatric diseases that the investigator considers inappropriate for this study.

    6. Subjects with a history of drug abuse or drug use within 1 year before screening; or subjects with positive result in a drug abuse screening (urine) (which cannot be justified by concurrent medications, such as those used for treating pain, anxiety, or insomnia as complications of renal disorder) at screening.

    7.Subjects who have received a vaccine within 2 weeks before screening or are planning to be vaccinated during the study or within 1 month postdose.

    8.Subjects who are positive for any indicator of (HIV) antibody, Treponema pallidum antibody, virus (HBV) surface antigen (HBsAg) or virus (HCV) antibody at screening.

    9.Subjects deemed unsuitable for inclusion by the investigator for other reasons.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    GZR18 injection

    Drug: GZR18 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax:Maximum plasma concentration

    Time frame: through study completion, an average of 36 days

  2. AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.

    Time frame: through study completion, an average of 36 days

  3. AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose.

    Time frame: through study completion, an average of 36 days

Secondary outcomes

  1. AUC0-336 h:Area under the plasma concentration-time curve from time zero to 336 hours

    Time frame: through study completion, an average of 36 days

  2. Tmax:Time of Maximum Drug ConcentrationTime to Maximum aentration

    Time frame: through study completion, an average of 36 days

  3. TEAE:Treatment Emergent Adverse Event

    Time frame: through study completion, an average of 36 days

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Oct 2025, 6 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Oct 2025, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 26, 2025
StartActual
Apr 11, 2025
Primary completionActual
Oct 20, 2025
CompletionActual
Oct 20, 2025was Mar 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Oct 9, 2025→Oct 20, 2025
Nov 10, 2026
Study completion
Mar 31, 2026→Oct 20, 2025 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Oct 9, 2025→Oct 20, 2025
    Study completion Mar 31, 2026→Oct 20, 2025 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07141030
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Apr 11, 2025
Primary completion
Oct 20, 2025
Completion
Oct 20, 2025
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion